Physician profile
David Lurie
NPI 1083675706
$5,288.14
in general payments reported to CMS, 2019-2025
14 companies · $852 in 2025
The $852 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $578 · 2021: $515 · 2022: $715 · 2023: $819 · 2024: $840 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,490.21 | 2019-2025 | |
| Pfizer INC. | $909.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $737.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $390.41 | 2019-2024 | Benlysta |
| Amgen INC. | $241.86 | 2019-2025 | Enbrel, Otezla, Evenity |
| Celgene Corporation | $108.33 | 2019 | |
| Ucb, INC. | $70.74 | 2022-2024 | Cimzia |
| Horizon Therapeutics Plc | $70.61 | 2019-2022 | |
| Janssen Biotech, INC. | $60.84 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $51.05 | 2024-2025 | Acthar |
| Genzyme Corporation | $46.39 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $42.27 | 2019-2020 | |
| Genentech USA, INC. | $37.88 | 2024 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.28 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lurie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.